Enhancing Parkinson’s Disease Symptom Improvement and Decreasing Adverse Event Incidence from L-DOPA Therapy by Improving L-DOPA Bioavailability and Consistency of Absorption through Co-administration of the Motilin Agonist, GSK962040


GRANT ABSTRACT

Objective/Rationale:
Parkinson’s disease often results in slower than normal emptying of food and medications from their stomach. This delayed gastric emptying is estimated to affect 50-90% of Parkinson’s disease patients. L-DOPA is absorbed when it reaches the upper intestine. If gastric emptying is delayed, L-DOPA may be erratically absorbed resulting in slowing to relief of patient symptoms and contribute to “on-off fluctuations.” GSK962040 is a new medication which in research studies has been shown to increase the speed at which the stomach empties. This project will study the effects of GSK962040 in people with Parkinson’s and delayed gastric emptying.

https://www.michaeljfox.org/foundati...?grant_id=1043